{"id":"asacol-mesalamine","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-5","effect":"Nausea"},{"rate":"1-3","effect":"Rash"},{"rate":"<1","effect":"Nephrotoxicity (rare)"}]},"_chembl":{"chemblId":"CHEMBL704","moleculeType":"Small molecule","molecularWeight":"153.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mesalamine (5-aminosalicylic acid) works primarily through local anti-inflammatory effects in the gastrointestinal tract. It inhibits the production of inflammatory mediators including prostaglandins and leukotrienes, and may also act as a free radical scavenger. The drug is delivered in formulations designed to release the active compound in the colon where it exerts its therapeutic effect on inflamed tissue.","oneSentence":"Mesalamine is an anti-inflammatory agent that acts locally in the colon to reduce inflammation by inhibiting prostaglandin and leukotriene production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:50.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ulcerative colitis (induction and maintenance of remission)"},{"name":"Crohn's disease (adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT05213234","phase":"NA","title":"Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rush University Medical Center","startDate":"2021-07-09","conditions":"Ulcerative Colitis","enrollment":32},{"nctId":"NCT05986136","phase":"PHASE2, PHASE3","title":"Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2023-08-20","conditions":"Inflammatory Bowel Diseases","enrollment":50},{"nctId":"NCT06335160","phase":"NA","title":"Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-04-20","conditions":"Ulcerative Colitis","enrollment":46},{"nctId":"NCT07389824","phase":"NA","title":"Efficacy of Acupuncture-Mesalazine Combination Therapy in Ulcerative Colitis.","status":"NOT_YET_RECRUITING","sponsor":"Qin Yu","startDate":"2026-02-01","conditions":"Ulcerative Colitis","enrollment":80},{"nctId":"NCT07333716","phase":"PHASE2","title":"Desloratadine in Patients With Ulcerative Colitis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2026-01-26","conditions":"Ulcerative Colitis (UC), Ulcerative Colitis","enrollment":44},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT07349472","phase":"PHASE2","title":"Pentoxifylline in Patients With Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Ihab Elsayed Hassan","startDate":"2026-01-20","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT07296315","phase":"PHASE2","title":"Confirmatory Clinical Study in Active Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"MRM Health NV","startDate":"2026-03","conditions":"Colitis, Ulcerative","enrollment":204},{"nctId":"NCT06998693","phase":"","title":"A Single-Center Observational Study on the Impact of Symptom Assessment Timing on the Short-Term Efficacy of 5-ASA Therapy in Patients With Initial-Onset or Relapsed Mild-to-Moderate Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-08-01","conditions":"Ul","enrollment":180},{"nctId":"NCT07248644","phase":"PHASE4","title":"Discontinuation of Thiopurine Therapy in Elderly Patients With Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","startDate":"2026-03-01","conditions":"Ulcerative Colitis (UC)","enrollment":304},{"nctId":"NCT07064707","phase":"PHASE2","title":"Rupatadine in Patients With Ulcerative Colitis","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-07-15","conditions":"Ulcerative Colitis","enrollment":60},{"nctId":"NCT06201793","phase":"PHASE2","title":"Minocyclin in Ulcerative Colitis as Added on Therapy","status":"COMPLETED","sponsor":"Mostafa Bahaa","startDate":"2024-01-22","conditions":"Inflammatory Bowel Diseases","enrollment":46},{"nctId":"NCT05567068","phase":"PHASE2","title":"Atorvastatin Efficacy and Safety in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-02-01","conditions":"Inflammatory Bowel Diseases","enrollment":54},{"nctId":"NCT07180186","phase":"","title":"Microbiota and Probiotic Therapy in Ulcerative Colitis Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-01-01","conditions":"Microbiota, Probiotic Therapy, Ulcerative Colitis","enrollment":70},{"nctId":"NCT05316220","phase":"PHASE3","title":"A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2025-09-15","conditions":"Ulcerative Colitis (UC)","enrollment":""},{"nctId":"NCT05988528","phase":"PHASE2, PHASE3","title":"Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis","status":"COMPLETED","sponsor":"Mostafa Bahaa","startDate":"2023-08-20","conditions":"Inflammatory Bowel Diseases","enrollment":50},{"nctId":"NCT05561062","phase":"PHASE2","title":"Atorvastatin in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-12-01","conditions":"Inflammatory Bowel Diseases","enrollment":50},{"nctId":"NCT05558761","phase":"PHASE2","title":"Pentoxifylline as Adjunctive Therapy in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-10-10","conditions":"Inflammatory Bowel Diseases","enrollment":50},{"nctId":"NCT05663775","phase":"PHASE2","title":"Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2024-08-20","conditions":"Immune-related Adverse Event, Diarrhea, Advanced Melanoma","enrollment":20},{"nctId":"NCT06993974","phase":"PHASE2","title":"Nitazoxanide in Patients With Ulcerative Colitis","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-05-30","conditions":"Ulcerative Colitis","enrollment":70},{"nctId":"NCT06878495","phase":"NA","title":"Efficacy and Safety of Discontinuing 5-ASA in Patients With Inflammatory Bowel Disease","status":"NOT_YET_RECRUITING","sponsor":"Pusan National University Hospital","startDate":"2025-06-15","conditions":"Ulcerative Colitis (UC), Crohn&#39;s Disease, Inflammatory Bowel Disease (IBD)","enrollment":100},{"nctId":"NCT03261206","phase":"PHASE4","title":"Stopping Aminosalicylate Therapy in Inactive Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2017-11-20","conditions":"Crohn Disease, Remission","enrollment":334},{"nctId":"NCT05553704","phase":"PHASE2","title":"Metformin in Patients With Ulcerative Colitis Treated With Mesalamine","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-11-01","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT05781698","phase":"PHASE2","title":"Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-03-20","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT06895252","phase":"NA","title":"A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Newly Diagnosed Active Ulcerative Colitis","status":"RECRUITING","sponsor":"All India Institute of Medical Sciences","startDate":"2025-03-15","conditions":"Ulcerative Colitis (UC)","enrollment":220},{"nctId":"NCT05753267","phase":"PHASE2, PHASE3","title":"Fenofibrate in Ulcerative Colitis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-02-28","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT06213857","phase":"PHASE2","title":"Beneficial Effect of Silymarin in Ulcerative Colitis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-02-01","conditions":"Ulcerative Colitis","enrollment":44},{"nctId":"NCT05575505","phase":"PHASE2","title":"Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-02-02","conditions":"Inflammatory Bowel Diseases","enrollment":44},{"nctId":"NCT05574387","phase":"PHASE2","title":"Metformin as Added on Therapy in Patients With Ulcerative Colitis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-01-20","conditions":"Inflammatory Bowel Diseases","enrollment":46},{"nctId":"NCT03591770","phase":"PHASE4","title":"Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-07-31","conditions":"Inflammatory Bowel Diseases","enrollment":15},{"nctId":"NCT05119140","phase":"PHASE1, PHASE2","title":"Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2022-06-10","conditions":"Ulcerative Colitis (Disorder)","enrollment":3},{"nctId":"NCT06067698","phase":"NA","title":"Alpha Lipoic Acid in Ulcerative Colitis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-10-01","conditions":"Ulcerative Colitis, Ulcerative Colitis (UC)","enrollment":60},{"nctId":"NCT05684484","phase":"PHASE4","title":"Role of Roflumilast in Ulcerative Colitis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-02-01","conditions":"Ulcerative Colitis","enrollment":52},{"nctId":"NCT04920149","phase":"PHASE2","title":"Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome","status":"RECRUITING","sponsor":"Ann-Sofie Backman","startDate":"2022-03-21","conditions":"Lynch Syndrome, Colon Cancer, Colon Neoplasm","enrollment":150},{"nctId":"NCT06625450","phase":"PHASE4","title":"TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS","status":"NOT_YET_RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2024-10","conditions":"Ulcerative Colitis","enrollment":75},{"nctId":"NCT06568224","phase":"","title":"Therapeutic Effect of Methalazine on 27 Cases of Suppurative Hidradenitis","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-05-01","conditions":"Hidradenitis Suppurativa","enrollment":27},{"nctId":"NCT00840203","phase":"PHASE1","title":"Mesalamine 4 gm/60 mL Rectal Enema","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT06525974","phase":"EARLY_PHASE1","title":"Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With Mesalamine","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2024-09-01","conditions":"Ulcerative Colitis","enrollment":46},{"nctId":"NCT04999241","phase":"PHASE4","title":"Combined Application of EEN in the Induction of Remission in PUC","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-03-01","conditions":"Exclusive Enteral Nutrition, Ulcerative Colitis, Children","enrollment":40},{"nctId":"NCT03283085","phase":"PHASE3","title":"A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)","status":"COMPLETED","sponsor":"Shire","startDate":"2018-02-27","conditions":"Crohn's Disease, Ulcerative Colitis","enrollment":557},{"nctId":"NCT05992142","phase":"PHASE4","title":"ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA","status":"COMPLETED","sponsor":"Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW","startDate":"2023-01-17","conditions":"Ulcerative Colitis","enrollment":200},{"nctId":"NCT04999228","phase":"PHASE4","title":"Top Down Versus Step up in Pediatric Ulcerative Colitis","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2021-11-01","conditions":"Ulcerative Colitis, Infliximab, Children","enrollment":40},{"nctId":"NCT06176560","phase":"PHASE3","title":"Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.","status":"UNKNOWN","sponsor":"Faes Farma, S.A.","startDate":"2024-03","conditions":"Colitis, Ulcerative","enrollment":376},{"nctId":"NCT05205603","phase":"PHASE4","title":"Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2022-01-15","conditions":"Ulcerative Colitis, Efficacy, Self, Biologics","enrollment":438},{"nctId":"NCT02291523","phase":"PHASE1","title":"The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis","status":"UNKNOWN","sponsor":"Children's Hospital Los Angeles","startDate":"2016-11-01","conditions":"Ulcerative Colitis","enrollment":101},{"nctId":"NCT04133194","phase":"PHASE4","title":"Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis","status":"UNKNOWN","sponsor":"Flemming Bendtsen","startDate":"2019-11-28","conditions":"Ulcerative Colitis","enrollment":200},{"nctId":"NCT05488405","phase":"PHASE2","title":"Mesalazine Oral Suspension in Active Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2023-02-09","conditions":"Eosinophilic Esophagitis","enrollment":5},{"nctId":"NCT03445624","phase":"","title":"Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-07-01","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT06013696","phase":"NA","title":"Bleach and Urine Color in UC Patients Using 5ASA","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2023-07-16","conditions":"Ulcerative Colitis","enrollment":40},{"nctId":"NCT05014555","phase":"","title":"Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"GI Alliance","startDate":"2023-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":400},{"nctId":"NCT02537210","phase":"NA","title":"Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2015-09","conditions":"Colitis, Ulcerative, Aminosalicylic Acid","enrollment":177},{"nctId":"NCT05626166","phase":"PHASE3","title":"the Efficacy and Safety of Diosmin in Patients With Ulcerative Colitis","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-12-15","conditions":"Ulcerative Colitis","enrollment":60},{"nctId":"NCT03441893","phase":"PHASE1, PHASE2","title":"Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis","status":"UNKNOWN","sponsor":"Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan","startDate":"2015-01-01","conditions":"Ulcerative Colitis, Ulcerative Colitis Exacerbation, Protozoan Infections","enrollment":300},{"nctId":"NCT02962245","phase":"PHASE4","title":"Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis","status":"WITHDRAWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2016-11","conditions":"Ulcerative Colitis","enrollment":""},{"nctId":"NCT02769494","phase":"PHASE3","title":"The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer","status":"WITHDRAWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2016-03","conditions":"Crohn's Disease, Oral Ulcer","enrollment":""},{"nctId":"NCT05538026","phase":"NA","title":"Effectiveness of Fecal Microbiota Transplantation as add-on Therapy in Mild-to-moderate Ulcerative Colitis","status":"COMPLETED","sponsor":"Bogomolets National Medical University","startDate":"2020-09-01","conditions":"Ulcerative Colitis Chronic Mild, Inflammatory Bowel Diseases","enrollment":53},{"nctId":"NCT04499495","phase":"","title":"Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2021-10-25","conditions":"Ulcerative Colitis","enrollment":11385},{"nctId":"NCT03980405","phase":"NA","title":"Combination of Diet and 5ASA ( 5-aminosalicylic Acid) for Ulcerative Colitis","status":"TERMINATED","sponsor":"Prof. Arie Levine","startDate":"2020-04-01","conditions":"Ulcerative Colitis","enrollment":12},{"nctId":"NCT05386290","phase":"","title":"A Multicentered Prospective Cohort Study of Chinese IBD Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-07-09","conditions":"Ulcerative Colitis, Crohn Disease","enrollment":200},{"nctId":"NCT02684734","phase":"","title":"Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative Colitis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2015-12","conditions":"Ulcerative Colitis, Cytomegalovirus Infections","enrollment":50},{"nctId":"NCT02261636","phase":"","title":"Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2015-01","conditions":"Ulcerative Colitis","enrollment":150},{"nctId":"NCT01941589","phase":"PHASE4","title":"Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2013-09","conditions":"Ulcerative Colitis","enrollment":149},{"nctId":"NCT03773952","phase":"PHASE2","title":"Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients","status":"COMPLETED","sponsor":"Palobiofarma SL","startDate":"2018-07-01","conditions":"Ulcerative Colitis","enrollment":34},{"nctId":"NCT02522780","phase":"PHASE3","title":"Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2016-02-01","conditions":"Ulcerative Colitis","enrollment":276},{"nctId":"NCT02493712","phase":"PHASE2","title":"A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M","status":"COMPLETED","sponsor":"Holy Stone Healthcare Co., Ltd","startDate":"2016-01","conditions":"Colitis, Ulcerative","enrollment":51},{"nctId":"NCT05091775","phase":"PHASE1, PHASE2","title":"The Efficacy of Asacol (Mesalazine) Suppository on the Treatment of Diarrhea-Induced Acute Fissure","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2020-06-01","conditions":"Fissure in Ano, Diarrhea","enrollment":140},{"nctId":"NCT00802451","phase":"NA","title":"Bioavailability Study of Two Mesalamine 4 gm/60 ml Rectal Enema Formulations","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2003-02","conditions":"Healthy","enrollment":48},{"nctId":"NCT02277223","phase":"PHASE3","title":"Curcumin in Pediatric Ulcerative Colitis","status":"WITHDRAWN","sponsor":"Schneider Children's Medical Center, Israel","startDate":"2020-03-01","conditions":"Ulcerative Colitis","enrollment":""},{"nctId":"NCT03104036","phase":"PHASE2","title":"Faecal Bacteriotherapy for Ulcerative Colitis","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2017-06-19","conditions":"Ulcerative Colitis","enrollment":61},{"nctId":"NCT02665845","phase":"PHASE3","title":"Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis).","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2016-06-13","conditions":"Ulcerative Colitis","enrollment":160},{"nctId":"NCT02930343","phase":"PHASE3","title":"Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy","status":"TERMINATED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2016-09","conditions":"Rheumatoid Arthritis","enrollment":136},{"nctId":"NCT04969679","phase":"PHASE4","title":"Additive Effect of Probiotics (Mutaflor®) in Patients With Ulcerative Colitis on 5-ASA Treatment.","status":"COMPLETED","sponsor":"Kangbuk Samsung Hospital","startDate":"2018-03-16","conditions":"Ulcerative Colitis","enrollment":134},{"nctId":"NCT01469637","phase":"PHASE1","title":"Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-11-07","conditions":"Healthy","enrollment":44},{"nctId":"NCT00151944","phase":"PHASE3","title":"Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.","status":"COMPLETED","sponsor":"Shire","startDate":"2003-11-26","conditions":"Colitis, Ulcerative","enrollment":400},{"nctId":"NCT01130844","phase":"PHASE1","title":"Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2010-10-08","conditions":"Ulcerative Colitis","enrollment":52},{"nctId":"NCT00545740","phase":"PHASE3","title":"Prevention of Recurrence of Diverticulitis","status":"COMPLETED","sponsor":"Shire","startDate":"2007-11-28","conditions":"Diverticulitis","enrollment":590},{"nctId":"NCT00151892","phase":"PHASE3","title":"Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2005-04-08","conditions":"Ulcerative Colitis","enrollment":829},{"nctId":"NCT00446849","phase":"PHASE4","title":"Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Shire","startDate":"2007-05-01","conditions":"Ulcerative Colitis","enrollment":290},{"nctId":"NCT00545103","phase":"PHASE3","title":"Prevention of Recurrence of Diverticulitis","status":"COMPLETED","sponsor":"Shire","startDate":"2007-12-06","conditions":"Diverticulitis","enrollment":592},{"nctId":"NCT00545389","phase":"PHASE2","title":"Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476","status":"COMPLETED","sponsor":"Shire","startDate":"2003-02-10","conditions":"Colitis, Ulcerative","enrollment":38},{"nctId":"NCT00548574","phase":"PHASE3","title":"Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2003-12-04","conditions":"Ulcerative Colitis","enrollment":343},{"nctId":"NCT01418365","phase":"PHASE1","title":"Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-08-22","conditions":"Healthy","enrollment":30},{"nctId":"NCT01402947","phase":"PHASE1","title":"Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-07-25","conditions":"Healthy","enrollment":30},{"nctId":"NCT01124149","phase":"PHASE4","title":"Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2010-06-29","conditions":"Ulcerative Colitis","enrollment":759},{"nctId":"NCT02093663","phase":"PHASE3","title":"Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis","status":"COMPLETED","sponsor":"Shire","startDate":"2014-12-12","conditions":"Ulcerative Colitis","enrollment":107},{"nctId":"NCT01442688","phase":"PHASE1","title":"Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-07","conditions":"Healthy","enrollment":62},{"nctId":"NCT02125292","phase":"PHASE1","title":"Taste Assessment Study of SHP429 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shire","startDate":"2014-06-02","conditions":"Healthy","enrollment":18},{"nctId":"NCT03923478","phase":"PHASE1","title":"ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis","status":"TERMINATED","sponsor":"Assembly Biosciences","startDate":"2019-06-24","conditions":"Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate","enrollment":15},{"nctId":"NCT02522767","phase":"PHASE3","title":"Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2015-10","conditions":"Ulcerative Colitis","enrollment":228},{"nctId":"NCT03689673","phase":"","title":"Study of the Effectiveness of ETIASA® (Sustained Release 5-Aminosalicylate) in Maintenance Treatment of Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Ipsen","startDate":"2013-04-24","conditions":"Ulcerative Colitis","enrollment":607},{"nctId":"NCT01412372","phase":"PHASE3","title":"The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study","status":"COMPLETED","sponsor":"University of Utah","startDate":"2010-06","conditions":"Irritable Bowel Syndrome","enrollment":61},{"nctId":"NCT00659802","phase":"PHASE2","title":"Phase II Study of HMPL-004 in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2008-02-07","conditions":"Ulcerative Colitis","enrollment":224},{"nctId":"NCT03412682","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2018-03-02","conditions":"Colitis, Ulcerative","enrollment":274},{"nctId":"NCT03096717","phase":"","title":"Dysplasia in Inflammatory Chronic Idiopathic Colitis Long-standing","status":"UNKNOWN","sponsor":"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis","startDate":"2017-01-01","conditions":"Dysplasia in IBD","enrollment":300},{"nctId":"NCT03399903","phase":"PHASE1, PHASE2","title":"Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection","status":"COMPLETED","sponsor":"AIDS Healthcare Foundation","startDate":"2017-05-01","conditions":"HIV-1-infection, Gut Inflammation","enrollment":47},{"nctId":"NCT00708656","phase":"PHASE3","title":"The Colitis Once Daily Asacol Study","status":"COMPLETED","sponsor":"Cardiff and Vale University Health Board","startDate":"2006-10","conditions":"Ulcerative Colitis","enrollment":213},{"nctId":"NCT02280629","phase":"PHASE3","title":"Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2014-10-01","conditions":"Ulcerative Colitis","enrollment":150},{"nctId":"NCT03415711","phase":"NA","title":"PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis","status":"TERMINATED","sponsor":"VSL Pharmaceuticals","startDate":"2017-04-28","conditions":"Ulcerative Colitis","enrollment":14},{"nctId":"NCT02910245","phase":"PHASE3","title":"Mercaptopurine Therapy in Ulcerative Colitis","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2016-11","conditions":"Colitis, Ulcerative","enrollment":136},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ADVERSE EVENT"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"AORTIC VALVE DISEASE"},{"count":1,"reaction":"HYPERAESTHESIA"},{"count":1,"reaction":"LYMPHOCYTE COUNT DECREASED"},{"count":1,"reaction":"PAIN"}],"_approvalHistory":[],"publicationCount":1383,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mesalamine"],"phase":"marketed","status":"active","brandName":"Asacol (mesalamine)","genericName":"Asacol (mesalamine)","companyName":"University of Washington","companyId":"university-of-washington","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mesalamine is an anti-inflammatory agent that acts locally in the colon to reduce inflammation by inhibiting prostaglandin and leukotriene production. Used for Ulcerative colitis (induction and maintenance of remission), Crohn's disease (adjunctive therapy).","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1987-12-24T00:00:00.000Z","mah":"MYLAN SPECIALITY LP","brand_name_local":"SFROWASA","application_number":"NDA019618"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2004-09-17T00:00:00.000Z","mah":"PADAGIS ISRAEL","brand_name_local":"MESALAMINE","application_number":"ANDA076751"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2004-09-30T00:00:00.000Z","mah":"G AND W LABS INC","brand_name_local":"MESALAMINE","application_number":"ANDA076841"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-05-29T00:00:00.000Z","mah":"ABBVIE","brand_name_local":"ASACOL HD","application_number":"NDA021830"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-10-31T00:00:00.000Z","mah":"SALIX","brand_name_local":"APRISO","application_number":"NDA022301"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-11-24T00:00:00.000Z","mah":"QUAGEN","brand_name_local":"MESALAMINE","application_number":"ANDA204354"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-06-05T00:00:00.000Z","mah":"ZYDUS PHARMS","brand_name_local":"MESALAMINE","application_number":"ANDA091640"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-07-21T00:00:00.000Z","mah":"ZYDUS PHARMS","brand_name_local":"MESALAMINE","application_number":"ANDA203286"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-03-23T00:00:00.000Z","mah":"ACTAVIS LABS FL","brand_name_local":"MESALAMINE","application_number":"ANDA203817"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-11-20T00:00:00.000Z","mah":"MYLAN","brand_name_local":"MESALAMINE","application_number":"ANDA203574"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-01-25T00:00:00.000Z","mah":"SUN PHARM","brand_name_local":"MESALAMINE","application_number":"ANDA211858"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-04-19T00:00:00.000Z","mah":"RISING","brand_name_local":"MESALAMINE","application_number":"ANDA207448"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-05-09T00:00:00.000Z","mah":"TEVA PHARMS USA","brand_name_local":"MESALAMINE","application_number":"ANDA207873"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-06-21T00:00:00.000Z","mah":"AMRING PHARMS","brand_name_local":"MESALAMINE","application_number":"ANDA208362"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-11-20T00:00:00.000Z","mah":"MYLAN","brand_name_local":"MESALAMINE","application_number":"ANDA207271"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-01-02T00:00:00.000Z","mah":"AMNEAL","brand_name_local":"MESALAMINE","application_number":"ANDA210509"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-02-12T00:00:00.000Z","mah":"ZYDUS PHARMS","brand_name_local":"MESALAMINE","application_number":"ANDA208953"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-03-19T00:00:00.000Z","mah":"ANNORA PHARMA","brand_name_local":"MESALAMINE","application_number":"ANDA213377"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-08-14T00:00:00.000Z","mah":"ACTAVIS MID ATLANTIC","brand_name_local":"MESALAMINE","application_number":"ANDA205654"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-07-15T00:00:00.000Z","mah":"ALKEM LABS LTD","brand_name_local":"MESALAMINE","application_number":"ANDA214242"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-08-12T00:00:00.000Z","mah":"ZYDUS PHARMS","brand_name_local":"MESALAMINE","application_number":"ANDA208954"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-05-06T00:00:00.000Z","mah":"TEVA PHARMS USA","brand_name_local":"MESALAMINE","application_number":"ANDA209970"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-05-11T00:00:00.000Z","mah":"SUN PHARM","brand_name_local":"MESALAMINE","application_number":"ANDA214585"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-10-28T00:00:00.000Z","mah":"ALEMBIC","brand_name_local":"MESALAMINE","application_number":"ANDA216967"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-03-31T00:00:00.000Z","mah":"AUROBINDO PHARMA LTD","brand_name_local":"MESALAMINE","application_number":"ANDA214477"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-05-12T00:00:00.000Z","mah":"SINOTHERAPEUTICS INC","brand_name_local":"MESALAMINE","application_number":"ANDA217337"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-05-30T00:00:00.000Z","mah":"ENCUBE","brand_name_local":"MESALAMINE","application_number":"ANDA216941"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-06-06T00:00:00.000Z","mah":"AMTA","brand_name_local":"MESALAMINE","application_number":"ANDA217533"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-02-05T00:00:00.000Z","mah":"ANNORA PHARMA","brand_name_local":"MESALAMINE","application_number":"ANDA216334"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-08-22T00:00:00.000Z","mah":"TEVA PHARMS INC","brand_name_local":"MESALAMINE","application_number":"ANDA213191"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-08-22T00:00:00.000Z","mah":"NOVAST LABS","brand_name_local":"MESALAMINE","application_number":"ANDA218410"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-04-14T00:00:00.000Z","mah":"RISING","brand_name_local":"MESALAMINE","application_number":"ANDA219028"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-04-16T00:00:00.000Z","mah":"NOVITIUM PHARMA","brand_name_local":"MESALAMINE","application_number":"ANDA215269"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2026-03-10T00:00:00.000Z","mah":"DIFGEN PHARMS","brand_name_local":"MESALAMINE","application_number":"ANDA219997"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2026-03-31T00:00:00.000Z","mah":"KLM LABS PVT","brand_name_local":"MESALAMINE","application_number":"ANDA220016"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}